期刊
DIABETES CARE
卷 44, 期 4, 页码 960-968出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc20-2684
关键词
-
资金
- vTv
- University of North Carolina Department of Medicine Physician Scientist Training Program
- Center for Scientific Review of the National Institutes of Health [UL1TR002489, P30DK124723]
- Patient-Centered Outcomes Research Institute
- American Diabetes Association
- JDRF
TTP399 lowers HbA(1c) levels and reduces the incidence of hypoglycemia without increasing the risk of ketosis. It should be further evaluated as an adjunctive therapy for type 1 diabetes.
OBJECTIVE Despite advances in exogenous insulin therapy, many patients with type 1 diabetes do not achieve acceptable glycemic control and remain at risk for ketosis and insulin-induced hypoglycemia. We conducted a randomized controlled trial to determine whether TTP399, a novel hepatoselective glucokinase activator, improved glycemic control in people with type 1 diabetes without increasing hypoglycemia or ketosis. RESEARCH DESIGN AND METHODS SimpliciT1 was a phase 1b/2 adaptive study. Phase 2 activities were conducted in two parts. Part 1 randomly assigned 20 participants using continuous glucose monitors and continuous subcutaneous insulin infusion (CSII). Part 2 randomly assigned 85 participants receiving multiple daily injections of insulin or CSII. In both parts 1 and 2, participants were randomly assigned to 800 mg TTP399 or matched placebo (fully blinded) and treated for 12 weeks. The primary end point was change in HbA(1c) from baseline to week 12. RESULTS The difference in change in HbA(1c) from baseline to week 12 between TTP399 and placebo was -0.7% (95% CI -1.3, -0.07) in part 1 and -0.21% (95% CI -0.39, -0.04) in part 2. Despite a greater decrease in HbA(1c) with TTP399, the frequency of severe or symptomatic hypoglycemia decreased by 40% relative to placebo in part 2. In both parts 1 and 2, plasma beta-hydroxybutyrate and urinary ketones were lower during treatment with TTP399 than placebo. CONCLUSIONS TTP399 lowers HbA(1c) and reduces hypoglycemia without increasing the risk of ketosis and should be further evaluated as an adjunctive therapy for the treatment of type 1 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据